Skip to content

    Concord Biotech

    CONCORDBIOGood
    Healthcare·14 Feb 2025
    Management Summary

    Concord Biotech reported a stable but muted Q3 FY25, characterized by revenue 'lumpiness' as global clients phased procurement into Q4. While quarterly growth was flat, the 9-month performance remains robust with 10% revenue growth and significant traction in the formulations business. Management is pivoting towards a medium-term CDMO strategy and preparing for the imminent launch of its injectable facility to drive future margins.

    Highlights

    8

    • Revenue from operations stood at ₹244 crores, a modest 1% YoY growth, impacted by customer procurement phasing.

    • EBITDA for the quarter was ₹98 crores with a healthy margin of 40.1%.

    • Profit After Tax (PAT) reached ₹76 crores with a 31.1% margin.

    • Formulation segment showed strong 9M FY25 growth of 42% YoY, reaching ₹192 crores.

    • API revenues (including interunit sales) grew by 9.6% YoY in Q3 FY25.

    • Injectable plant (Unit 4) is scheduled to begin commercial production in Q4 FY25.

    • Maintained long-term guidance of 25% CAGR growth over the next 5 years.

    • Company remains zero-debt with cash and equivalents of ₹250 crores as of December 31, 2024.

    Key financials

    Metrics

    5

    Periods

    2

    Headline

    4
    • Revenue
      ₹244 Cr
      YoY+1.6%
    • EBITDA
      ₹98 Cr
      YoY-6.6%
    • EBITDA Margin
      40.1%
    • PAT
      ₹76 Cr
      YoY-2%

    9M

    1
    • Revenue
      ₹770 Cr
      YoY+10.3%

    Segment breakdown

    • API₹176 Cr72.2%
    • Formulations₹67.6 Cr27.8%
    Donut· Share of Revenue

    Guidance & targets

    5
    CategoryTargetPriority
    Revenue
    Long-term Revenue CAGR
    25%
    		High
    Margin
    Sustainable EBITDA Margin
    40% to 43%
    		High
    Other
    New Product Introductions
    8 to 10
    		Medium
    Capex
    Maintenance Capex
    ₹15-20 crores
    		High
    Capacity
    Injectable Plant Commercialization
    Q4 FY25
    		High

    Risks & concerns

    5
    RiskSeverity

    Quarterly Revenue Lumpiness

    Customer procurement patterns and calendar year closures lead to sales being pushed between quarters. — Management acknowledged

    medium

    Slow Customer Transition to New Sites

    External customers are taking longer than anticipated to qualify the Limbasi facility for their requirements. — Analyst acknowledged

    medium

    Initial Margin Drag from Injectables

    The new injectable facility may act as a slight drag on margins during the initial ramp-up phase next year. — Management acknowledged

    low

    Areas of Evasion(2)

    • Molecule-wise revenue contribution
    • Specific volume percentage of API going to internal formulations

    Q&A highlights

    3

    “Given our order book position that we have and given that much of the phasing out has happened or the shift has happened to Quarter 4, we expect our Quarter 4 again to be on the higher side.”

    Clarifies that the current 10-12% growth is below the 18-20% target due to timing, but Q4 is expected to compensate.

    asked by Chintan Sheth, Girik Capital

    2 min read5 chapters

    Detailed Narrative

    01

    Muted Q3 Performance due to Phasing

    Concord Biotech reported a flat Q3 FY25 with revenue of ₹244 crores, representing only 1% YoY growth. Management attributed this to 'lumpiness' in customer procurement, with several global clients pushing orders from Q3 into Q4 due to calendar year closures. Despite the muted quarter, the company maintains a strong order book and expects a significant ramp-up in Q4 FY25 to align with its annual growth targets.

    02

    Formulation Segment as a Growth Engine

    The formulation business continues to be a standout performer, growing 42% YoY on a 9-month basis to reach ₹192 crores. While Q3 formulation revenue was slightly down at ₹67.6 crores due to tender timing, the company has built a robust sales team of over 200 members in India. Management expects this segment to continue its high-growth trajectory as it penetrates emerging markets and expands its product portfolio.

    03

    Capacity Utilization and Site Transfers

    Capacity utilization remains varied across facilities: Unit 1 (Dholka) is at 78%, Unit 2 (Formulations) at 26%, and the new Unit 3 (Limbasi) at 35%. Management noted that while internal formulation units have qualified the Limbasi site, external API customers are taking longer than expected to complete site qualifications. This transition is critical for increasing the utilization of the 800m³ fermentation capacity at Limbasi.

    04

    Strategic Entry into Injectables

    The company is on the verge of commercializing its injectable plant (Unit 4) in Q4 FY25. Concord has already invested ₹225 crores in this facility and plans to target the domestic market initially before filing for emerging markets. While the facility might cause a minor margin drag during its initial ramp-up, it is expected to contribute significantly to both revenue and profitability within 2-3 years.

    05

    Long-term Growth and Margin Sustainability

    Management reiterated its long-term guidance of a 25% CAGR over the next five years, supported by a pipeline of 8-10 new products. EBITDA margins are expected to remain in the sustainable range of 40% to 43%. The company's zero-debt status and ₹250 crores cash reserve provide a strong cushion for maintenance capex and strategic investments, such as the recent $1 million investment in Palvella Therapeutics.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.